VanEck Associates
BLRX

VanEck Associates’s BioLineRX BLRX Stock Holding History

VanEck Associates’s Portfolio BLRX Stock Details BLRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-92
Closed -$10K – 989
2019
Q3 		$10K Hold
92
– – ﹤0.01% 828
2019
Q2 		$20K Sell
92
-6
-6% -$1.35K ﹤0.01% 814
2019
Q1 		$25K Buy
98
+2
+2% +$582 ﹤0.01% 813
2018
Q4 		$25K Buy
96
+35
+57% +$16.8K ﹤0.01% 779
2018
Q3 		$39K Buy
61
+3
+5% +$1.65K ﹤0.01% 767
2018
Q2 		$31K Buy
58
+17
+41% +$9.03K ﹤0.01% 826
2018
Q1 		$21K Buy
41
+3
+8% +$1.84K ﹤0.01% 717
2017
Q4 		$25K Sell
38
-27
-42% -$17.8K ﹤0.01% 709
2017
Q3 		$44K Buy
65
+3
+5% +$1.86K ﹤0.01% 716
2017
Q2 		$31K Buy
+62
New +$31.9K ﹤0.01% 728

Other funds holding BLRX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
SM
Senvest Management New York $3.01B AUM 35.7% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
CCB
Cutter & Co Brokerage Ballwin, Missouri $423M AUM 15.02% 1-Year Est. Return
CAN
Cetera Advisor Networks El Segundo, California $20.2B AUM 22.31% 1-Year Est. Return
NFG
Next Financial Group Houston, Texas $1.52B AUM 20.14% 1-Year Est. Return
ADL
Asset Dedication LLC San Francisco, California $1.43B AUM 22.07% 1-Year Est. Return
RE
RBC Europe London, United Kingdom $2.08B AUM 12.2% 1-Year Est. Return

VanEck Associates's BLRX Position: Q4 2019 in Review

VanEck Associates sold out of BioLineRX (BLRX) in Q4 2019, closing a stake of 92 shares — an estimated $10K sold.

VanEck Associates first reported a position in BLRX in Q2 2017 and held it in 10 quarters. The position peaked at $44K in Q3 2017. 12 funds tracked by Wall St. Rank hold BLRX as of Q4 2019.

  • VanEck Associates reported no remaining BioLineRX position as of Q4 2019 after selling out during the quarter.
  • VanEck Associates sold 92 BioLineRX shares in Q4 2019, an estimated $10K.
  • VanEck Associates first reported a position in BioLineRX in Q2 2017 and held it in 10 quarters.
  • VanEck Associates's BioLineRX position peaked at $44K in Q3 2017.
  • 12 funds tracked by Wall St. Rank held BioLineRX as of Q4 2019.

Based on VanEck Associates's 13F filing for Q4 2019, filed 13 Feb 2020.